Aries Wealth Management increased its position in Pfizer Inc. (NYSE:PFE) by 4.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 40,501 shares of the biopharmaceutical company’s stock after buying an additional 1,555 shares during the quarter. Aries Wealth Management’s holdings in Pfizer were worth $1,486,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Schneider Downs Wealth Management Advisors LP bought a new stake in Pfizer during the third quarter valued at about $296,000. Strategic Investment Advisors MI boosted its stake in shares of Pfizer by 12.9% in the third quarter. Strategic Investment Advisors MI now owns 20,858 shares of the biopharmaceutical company’s stock worth $763,000 after acquiring an additional 2,381 shares during the period. Ridgewood Investments LLC grew its position in shares of Pfizer by 5.2% during the third quarter. Ridgewood Investments LLC now owns 21,927 shares of the biopharmaceutical company’s stock worth $805,000 after purchasing an additional 1,084 shares in the last quarter. Winfield Associates Inc. raised its stake in Pfizer by 34.7% during the 3rd quarter. Winfield Associates Inc. now owns 20,527 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 5,290 shares during the period. Finally, CRA Financial Services LLC lifted its holdings in Pfizer by 41.4% in the 3rd quarter. CRA Financial Services LLC now owns 19,196 shares of the biopharmaceutical company’s stock worth $704,000 after purchasing an additional 5,621 shares in the last quarter. 69.08% of the stock is owned by hedge funds and other institutional investors.

In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $38.55 per share, with a total value of $501,150.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at $154,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.08% of the company’s stock.

Several equities research analysts have recently issued reports on PFE shares. Morgan Stanley lifted their price objective on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Piper Sandler boosted their price target on shares of Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. Mizuho reaffirmed a “buy” rating and issued a $43.00 target price on shares of Pfizer in a report on Tuesday, September 15th. Finally, UBS Group increased their price target on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average target price of $39.64.

NYSE PFE opened at $37.95 on Friday. The business’s 50 day moving average price is $36.59 and its 200-day moving average price is $36.32. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $40.97. The company has a market cap of $210.88 billion, a P/E ratio of 15.06, a P/E/G ratio of 2.91 and a beta of 0.67. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The firm had revenue of $11.80 billion during the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business’s revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the business earned $0.80 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be paid a dividend of $0.38 per share. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s dividend payout ratio is 51.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Black Swan

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.